Cover Kidney News
Volume/Issue:
Volume 11: Issue 2
Page:
14–15
Publication Date:
01 Feb 2019
Online Publication Date:
07 Feb 2019
Figure 1.

The EMPA-REG OUTCOME trial
Figure 2.

The CANVAS clinical trial program
Figure 3.

Cardiovascular and renal outcomes with canagliflozin
Editorial Type:
Features

SGLT2 Inhibitors and Cardiorenal Outcomes

Brendon L. Neuen Brendon L. Neuen, MBBS(Hons), is a Clarendon Scholar at the Nuffield Department of Population Health, University of Oxford, UK. Edgar V. Lerma, MD, is clinical professor of medicine at the University of Illinois at Chicago College of Medicine. Joel Topf, MD, is Medical Director of St. Clair Nephrology Research in Roseville, MI.

Search for other papers by Brendon L. Neuen in
Current site
Google Scholar
PubMed Close
,
Edgar V. Lerma Brendon L. Neuen, MBBS(Hons), is a Clarendon Scholar at the Nuffield Department of Population Health, University of Oxford, UK. Edgar V. Lerma, MD, is clinical professor of medicine at the University of Illinois at Chicago College of Medicine. Joel Topf, MD, is Medical Director of St. Clair Nephrology Research in Roseville, MI.

Search for other papers by Edgar V. Lerma in
Current site
Google Scholar
PubMed Close
, and
Joel Topf Brendon L. Neuen, MBBS(Hons), is a Clarendon Scholar at the Nuffield Department of Population Health, University of Oxford, UK. Edgar V. Lerma, MD, is clinical professor of medicine at the University of Illinois at Chicago College of Medicine. Joel Topf, MD, is Medical Director of St. Clair Nephrology Research in Roseville, MI.

Search for other papers by Joel Topf in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 11: Issue 2
Publication Date:
01 Feb 2019
Page:
14–15
Restricted access
Save